<DOC>
	<DOCNO>NCT02461069</DOCNO>
	<brief_summary>This exploratory study , allow analysis multiple immune parameter derive peripheral blood mononuclear cell ( PBMCs ) patient relapse remit multiple sclerosis immune-modulatory treatment dimethyl fumarate comparison PBMCs healthy subject .</brief_summary>
	<brief_title>Investigation Effect Dimethyl Fumarate T Cells Patients With Relapsing Remitting Multiple Sclerosis</brief_title>
	<detailed_description>The purpose trial shed light mechanism action dimethyl fumarate patient relapse remit multiple sclerosis . More specifically influence dimethyl fumarate peripheral immune cell address evaluate change cytokine production distinct T cell subset differentiation capacity naïve T cell . Furthermore , impact dimethyl fumarate treatment migratory capacity T cell well evaluation change suppressive capacity regulatory T cell evaluate . To put obtain result context , response data dimethyl fumarate-treated patient compare data healthy subject .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Healthy subject : H1 . Written informed consent must obtain assessment perform . H2 . Male female subject age 18 60 year . H3 . No history multiple sclerosis clinically isolated syndrome . H4 . No history autoimmune disease , treat systemically corticosteroid , immunomodulators immunosuppressive drug time point . RRMS patient : MS1 . Written informed consent must obtain assessment perform . MS2 . Male female subject age 18 60 year . MS3 . Patients RRMS , define 2010 revise McDonald criterion . MS4 . Patients Expanded Disability Status Scale ( EDSS ) score 06.0 . MS5 . Patients one follow treatment status : Naïve disease modifying ( DM ) treatment ( i.e . DM treatment least 1 month ) , Currently MS therapy interferon β1 glatiramer acetate willing switch dimethyl fumarate ( Tecfidera® ) . RRMS patient : MS1 . Known hypersensitivity dimethyl fumarate ingredient Tecfidera® ( microcrystalline cellulose ; croscarmellosesodium ; talcum ; high dispersion , hydrophobic silicon dioxide ; magnesiumstearate ( Ph . Eur . ) ; triethylcitrate ; methacrylic acidmethacrylate copolymer ( 1:1 ) ( Ph . Eur . ) ; methacrylic acidethylacrylate copolymer ( 1:1 ) dispersion 30 % ( Ph . Eur . ) , simeticon , sodiumdodecylsulfate , polysorbate 80 , gelantine , titanium oxide ( E171 ) , brilliant blue ( E133 ) , hydrate Iron ( III ) oxide hydroxide ( E172 ) , shellac , potassium hydroxide . MS2 . A MSrelapse within 30 day prior screen . MS3 . Known history active tuberculosis active tuberculosis determine positive QuantiFERON® TB Gold test ( i.e . negative test result provide screen unless negative test result exist last 3 month prior screen ) . MS4 . Moderate severe impairment liver function persist elevation &gt; 2 x ULN ( confirm retest ) serum glutamic pyruvic transaminase/ alanine aminotransferase ( SGPT/ALT ) serum glutamic oxaloacetic transaminase/aspartate aminotransferase ( SGOT/AST ) , except patient confirm Gilbert´s syndrome ( Meulengracht´s disease ) . MS5 . Moderate severe impairment renal function , show serum creatinine &gt; 133 μmol/L ( &gt; 1.5 mg/dL ) . MS6 . Patients significantly impair bone marrow function significant anemia , leukopenia , neutropenia thrombocytopenia . MS7 . Women childbearing potential utilizing highly effective contraception . Both population : MS/H1 . Mental condition render subject unable understand nature , scope , possible consequence study . MS/H2 . Subjects unlikely comply protocol determine investigator , e.g. , uncooperative attitude , inability return followup visit ( e.g . major physical disability ) , know unlikelihood complete study . MS/H3 . Clinically relevant cardiovascular , neurological , endocrine , major systemic disease make implementation protocol interpretation study result difficult would put subject risk participate study . MS/H4 . Subjects ulcerative colitis Crohn´s disease . MS/H5 . Subjects congenital acquire severe immunodeficiency , history cancer ( except basal squamous cell skin lesion surgically excise , evidence metastasis ) , lymph proliferative disease , subject receive lymphoid irradiation . MS/H6 . Human immunodeficiency virus ( HIV ) positive , hepatitis B virus positive hepatitis C virus positive subject ( i.e . negative test result provide screening . In presence negative test result last 3 month prior screen , test repeat screening. ) . MS/H7 . Acute chronic infection . MS/H8 . History drug alcohol abuse . MS/H9 . Use adrenocorticotrophic hormone ( ACTH ) systemic corticosteroid 4 week prior screen . MS/H10 . Prior concomitant use cytokine therapy intravenous immunoglobulin 3 month prior screen . MS/H11 . Prior use alemtuzumab cladribine . MS/H12 . Prior use ( within 1 year ) fingolimod ( Gilenya® ) natalizumab ( Tysabri® ) . MS/H13 . Prior use ( within 2 year ) mitoxantrone , immunosuppressant agent azathioprine , cyclophosphamide , cyclosporine , methotrexate mycophenolate mofetil . MS/H14 . Prior treatment teriflunomide leflunomide , unless successful washout , confirm plasma concentration &lt; 0.02 μg/ml . MS/H15 . Prior use investigational drug 6 month precede screening . MS/H16 . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>dimethyl fumarate</keyword>
</DOC>